| Huang Tingting,Qiu Hong,Yuan Xianglin. Targeted therapy of gastric cancer: current and prospective strategies. Oncol Transl Med, 2018, 4: 41-47. |
| Targeted therapy of gastric cancer: current and prospective strategies |
| Received:March 30, 2018 Revised:May 17, 2018 |
| View Full Text View/Add Comment Download reader |
| KeyWord:gastric cancer; targeted therapy; clinical trials |
| Author Name | Affiliation | E-mail | | Huang Tingting | Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | huangttcx@163.com | | Qiu Hong | Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Yuan Xianglin | Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | xlyuan1020@163.com |
|
| Hits: 6378 |
| Download times: 10937 |
| Abstract: |
| Gastric cancer is the third leading cause of cancer-related death worldwide. Surgery is currently the only curative treatment strategy. Chemotherapy has shown limited efficacy in advanced gastric cancer patients with a median overall survival of less than one year. Thus, new treatments are urgently needed. Trastuzumab and Ramucirumab are the only targeted therapies approved currently. Most Phase III clinical trials evaluating targeted drugs in gastric cancer have failed. This review will evaluate relevant clinical trials with targeted therapies performed in gastric cancer patients, discuss the possible reasons for the failure, and indicate new possibilities to enhance gastric cancer treatment.
|
| Close |
|
|
|